A New Chapter: Lanton Law is now Lanton, Lanton & Sosa Law

By: The Partners of Lanton, Lanton & Sosa

We are thrilled to share some major news with our clients, colleagues, and friends.

If you’ve visited our website today or seen our recent press release, you likely noticed a change. Lanton Law, PLLC has officially rebranded to Lanton, Lanton & Sosa Law, PLLC.

This isn’t just a name change—it’s a reflection of how we are evolving to meet your needs. Over the past few years, our clients have asked for more support in complex areas like real estate, technology, and corporate growth. We listened, and today we are expanding our team and our practice to deliver exactly that.

Meet Our New Managing Partner

The "Sosa" in our new name belongs to Maria Sosa, whom we are honored to welcome as our new Managing Partner.

Maria is not just joining the leadership team; she is bringing an entirely new capability to the firm: Commercial Real Estate. Whether you are navigating property development or complex transactions, Maria’s expertise adds a critical pillar to the services we offer. She will also be heavily involved with our healthcare and technology clients, as well as with Lanton Strategies International. There she will be driving advocacy for our clients across the Northeast.

Expanded Services for a Changing World

Alongside this rebrand, our existing leadership is taking on new strategic roles to broaden our scope:

• Ron Lanton is now Senior Partner and Global Strategist. While he remains the dedicated General Counsel for our healthcare and life sciences clients, he is formally expanding his practice to include Mergers and Acquisitions (M&A). If your company is looking to grow, acquire, or exit, Ron is ready to guide that strategy.

• Casandra Lanton has been appointed Chief Legal Officer. She is expanding her expertise beyond Human Resources and Employment Law to include Technology Law, ensuring your business is protected in an increasingly digital and regulated environment.

Bridging D.C. and New England

We know that policy decisions made in Washington often have ripple effects on business operations in the Northeast. That is why we are solidifying our footprint.

• Headquarters: We remain rooted in Washington, D.C., at the center of legislative and regulatory affairs.

• Principal Operations: We have established a major operational hub in Boston, Massachusetts, allowing us to serve our New England clients more directly.

What This Means for You

If you are a current client, the only thing changing is our letterhead. You will continue to receive the same personalized, high-level counsel you rely on—now with even more resources at your disposal.

Thank you for trusting us with your business. We are excited to step into this future with you.

— The Team at Lanton, Lanton & Sosa Law, PLLC

Read the full official press release here.

Lanton Law Speaks with Drug Topics on Its Over the Counter Podcast on MFN

Ron Lanton of Lanton Law speaks with Drug Topics on their podcast episode of Over the Counter. Ron discusses developing policy expected to enact significant change in the pharmacy industry and beyond titled “Most Favored Nation: Global Benchmarking to Reimagine US Drug Distribution.” Click here to access the podcast.

Unpacking the Framework: Inside the US-UK Tech Prosperity Deal

While the recent suspension of the US-UK "Tech Prosperity Deal" has dominated the headlines, smart stakeholders know that to navigate the future, you must understand the blueprint. Signed during President Trump’s state visit to the UK in September 2025, this agreement was designed to be a "generational step-change" in the transatlantic special relationship.

Based on the Memorandum of Understanding and the US Embassy’s summary, here are the three core pillars of the deal that every tech and energy leader needs to know.

1. Artificial Intelligence: Aligning Standards & Science

The deal focuses heavily on regulatory alignment to prevent a fragmented AI market.

• Standards & Safety: It establishes a direct partnership between the U.S. Center for AI Standards and Innovation (CAISI) and the UK AI Security Institute (AISI) to harmonize model testing and risk management.

• AI for Science: A flagship program was created to link U.S. agencies (DOE, HHS, NSF) with UK counterparts to accelerate biotechnology breakthroughs, specifically in cancer research and precision medicine.

2. Civil Nuclear Energy: Cutting Red Tape & Russian Dependence

For the energy sector, the deal proposes a radical streamlining of regulatory hurdles.

• Faster Licensing: The agreement targets a timeline of just two years for reactor design reviews and one year for site licensing by aligning the U.S. Nuclear Regulatory Commission and UK Office for Nuclear Regulation.

• Energy Security: It commits the UK to full independence from Russian nuclear fuel by 2028, ensuring a secure, allied supply chain.

3. Quantum Computing: The Race for Standards

Recognizing that Quantum is the next frontier, the deal emphasizes interoperability. It creates a joint benchmarking task force to set shared standards for hardware and algorithms, ensuring that U.S. and UK quantum ecosystems can grow together rather than as competitors.

The "Operative" Clause

Crucially, the MOU includes a provision that the deal only becomes "operative" alongside progress on the broader Economic Prosperity Deal. This legal nuance is exactly why the current trade disputes have halted implementation—a reminder that in international agreements, the fine print always matters.

Call to Action Whether this deal is revived or renegotiated, the regulatory intent of both nations is clear. If your organization operates in AI, nuclear energy, or quantum computing, you need a strategy that anticipates these converging standards. Contact Lanton Strategies today to position your business for the future of transatlantic tech policy.

Policy Alert: What the £31bn Tech Deal Suspension Means for US and UK Innovation

With the Trump administration’s sudden suspension of the £31bn "Tech Prosperity Deal," the future of transatlantic innovation faces immediate and critical uncertainty. As reported, this landmark agreement—intended to bolster cooperation in AI, quantum computing, and civil nuclear energy—has been paused due to frustrations over non-tariff trade barriers and digital services taxes.

This development highlights the volatility of international trade agreements and the transactional nature of the current regulatory environment. To understand the full scope of the cooperation and specific provisions that are now at risk, I encourage stakeholders to review the details of the of the Memorandum of Understanding regarding the “Tech Prosperity Deal” click here.

The suspension places pledged investment from major tech players on ice and creates significant headwinds for innovation hubs in both nations. For stakeholders, this is a stark reminder that policy and prosperity are inextricably linked.

At Lanton Law and Lanton Strategies, we specialize in helping Transatlantic organizations navigate these complex government affairs and legal challenges. When the geopolitical landscape shifts, your strategy must adapt immediately.

Don't let diplomatic friction stall your innovation pipeline. Contact us today for strategic consulting on how this suspension impacts your business. Let’s discuss how we can help you pivot and thrive despite these headwinds.

New Trans-Atlantic Drug Pricing Deal: What Supply Chain Stakeholders Must Know

In a major development for the global life-sciences landscape, the United States and the United Kingdom have reached an agreement in principle that reshapes how both countries approach pharmaceutical pricing and cross-border trade.

Under the agreement, the U.K. will raise the net price of new medicines by 25%, reversing years of downward pressure that had strained returns on innovative therapies. The government will also ease the financial burden of its VPAG rebate structure, capping repayment levels and committing to maintain rebate rates at or below approximately 15% starting in 2026. These changes reflect a broader acknowledgment that sustaining innovation requires restoring reasonable margins across the branded pharmaceutical marketplace.

In exchange, the United States will exempt U.K.-origin pharmaceuticals, active ingredients, and medical technologies from current and prospective Section 232 tariffs. This concession reduces supply-chain volatility and removes a major source of uncertainty for U.S. companies sourcing components or finished products from the U.K. It also signals a more cooperative posture between two major life-sciences hubs as they seek to reinforce global competitiveness.

For 2026, this agreement provides both opportunity and complexity. Companies should monitor how implementation unfolds and assess how pricing, market access, and supply-chain exposure may shift.

If you are a pharmaceutical supply-chain stakeholder seeking help assessing potential risks or developing a 2026 strategy, contact Lanton Strategies today. Our team can guide you through the policy, regulatory, and market implications of this evolving landscape.

Lanton Law Returns to Moderate Most Favored Nation Panel for Pharmacy Times

Lanton Law retuned to moderate the third and final panel on MFN for Pharmacy Times titled “How Trump Is Disrupting Pharma: Exploring the Impacts of MFN, Tariffs and DTC on Drug Markets.” The panel discussion can be heard here.

Lanton Law Quoted in Bloomberg Law

We have been talking a lot lately about drug pricing; specifically Most Favored Nation (MFN) and other ancillary issues. We were recently quoted in Bloomberg Law News on the issue here. Thanks to Nyah Phengsitthy for reaching out.

Lanton Law Moderates Most Favored Nation Panel for MJH Life Sciences

Lanton Law was honored to be selected as a moderator for the MJH Life Sciences panel titled ““Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform.”

The AJMC wrote a nice blog post on the panel. The panelists, included moderator Ron Lanton, JD, of Lanton Law; Mel Whittington, PhD, managing director and head of the Leerink Center for Pharmacoeconomics at MEDACorp, Inc.; Stephen Forster, JD, partner at the Health Care and Life Sciences Practice at Jones Day; and Peter Rubin, executive director of No Patient Left Behind. The panel discussed the voluntary Pfizer agreement, which aims to reduce prices by up to 85%, and the new TrumpRx platform, set to launch in 2026 to allow direct-to-consumer medication purchases.

The Pharmaceutical Executive story on the panel can be found here.

The AJMC article on the panel can be viewed here.

Can America's Retreat On mRNA Be Europe's Opportunity?

Lanton Law has an article in Life Science Connect’s Advancing RNA titled “Can America's Retreat On mRNA Be Europe's Opportunity?”

With the unprecedented success of mRNA vaccines during the pandemic, it almost felt as though mRNA technology was about to enter a “golden era” where new solutions using this platform would be found to finally address costly and devastating diseases that had been wreaking havoc in many countries. Unfortunately, the steadfast rising skepticism in the U.S. about vaccines has caused a drastic change on mRNA from the U.S. Department of Health and Human Services (HHS).

To view the article click here.

Lawsuits Likely as Federal Authorities Roll Back Longstanding Vaccine Guidelines

In a recent interview with Pharmaceutical Executive, Ron Lanton, partner, Lanton Law, discussed the unprecedented legal and policy challenges emerging from recent changes to federal vaccine recommendations. The interview can be seen here.

Lanton Law Speaks on Clinical Ops Teams Maintaining Clinical Trial Integrity

Lanton Law spoke with Applied Clinical Trials on why evolving federal guidance and new technologies are pushing clinical operations teams to strengthen oversight and safeguard the credibility of clinical research.

The interview can be found here.

FDA FY 2026 Biosimilar Plan: Key Insights for Manufacturers and Investors

The FDA’s FY 2026 Legislative Proposal reaffirms its strong support for biosimilars as a key means to reduce drug costs and enhance competition. Building on its Biosimilars Action Plan, the Agency emphasizes streamlined approval pathways, enhanced interchangeability guidance, and policies aimed at overcoming scientific and manufacturing complexity. The FDA also signals that future resources will focus on advancing analytical tools and regulatory science to boost biosimilar adoption while safeguarding quality, safety, and efficacy.

Notably, the FDA underscores the importance of transparency and predictability—pillars of the Agency’s renewed commitment. This means clearer timelines, more robust FDA‑industry dialogue, and continued investment in research infrastructure to facilitate complex biologic comparisons. The proposal signals readiness to refine naming conventions, labeling standards, and post‑market surveillance to help manufacturers navigate biosimilar development while also ensuring clinician and patient confidence.

In short, the FDA is actively shaping an ecosystem that supports biosimilar innovation—with an eye on reducing health care spending and expanding patient access—while maintaining rigorous safety standards.

Navigating the evolving FDA landscape requires expert guidance. At Lanton Law, we help biosimilar manufacturers and partners strategize around regulatory hurdles, streamline business planning, and align submissions with FDA expectations. If you’re currently preparing for 2026 changes—especially concerning interchangeability, analytics, naming or the like—reach out to Lanton Law today for proactive, tailored counseling to position your biosimilar programs for success.

Rising API Tariffs Are Forcing Pharma to Shift R&D Resources

In Part 3 of our interview; Lanton Law speaks with Applied Clinical Trials on the highlights of how tariffs on active pharmaceutical ingredients could affect resources for maintaining and accelerating R&D pipelines. The interview can be heard here.

Lanton Law Talks to Applied Clinical Trials About How FDA Cuts Are Creating New Bottlenecks in Clinical Operations

In Part 2 of the interview; Ron Lanton, partner, Lanton Law, talks FDA layoffs and their impact on inspections and clinical trial timelines. The interview can be seen here.

Lanton Law Talks to Applied Clinical Trials About The Hidden Impact of Drug Pricing on Government Clinical Trials

In part one of this video interview, Ron Lanton III, Esq., partner, Lanton Law, discusses how a potential increase in drug costs could affect the clinical research industry. The interview can be seen here.

Bipartisan Bill Aimed At Expanding CMS Coverage Of Rx Digital Therapeutics Re-Introduced

The Access to Prescription Digital Therapeutics Act of 2025 (S1702/3288) seen here has been re-introduced by Senators Shelley Moore Capito (R-WV) and Jeanne Shaheen (D-NH)) and Representatives Kevin Hern (R-OK) and Mike Thompson (D-CA). The proposed legislation would do the following: 

• Create a reimbursement pathway for software that treats medical conditions

• Create a new Medicare benefit category for Food and Drug Administration (FDA)-cleared prescription digital therapeutics to be prescribed to seniors in the program.

• Require the CMS to develop payment methodologies for prescription digital therapeutics and create product-specific CPT codes to adequately reimburse for the products. 

Lanton Law through its Government Affairs Division Lanton Strategies has been following digital therapeutic policy as it unfolds. This is an oftentimes confusing area of policy since it is innovative and many times mistakenly tied to FDA approvals. 

Stakeholders who are interested in this issue and want to ensure compliance should ensure that an adequate and appropriate FDA approval and CMS reimbursement strategy is in place internally to avoid marketplace delays. Contact us to learn more.  

Lanton Law Interviewed by Pharmacy Times Over Prescription Drug Price Executive Order

Lanton Law was quoted in Pharmacy Times’ article titled “President Trump Signs Executive Order Aiming to Lower Prescription Drug Costs by Up to 90%.” The article can be accessed here.

Understanding the 2025 Executive Order on Most-Favored-Nation Drug Pricing: Implications for Healthcare Stakeholders

On May 12, 2025, President Trump signed an executive order titled "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients," aiming to align U.S. prescription drug prices with the lowest prices paid by other developed nations.

Key Provisions:

• Most-Favored-Nation (MFN) Pricing: The order mandates that Americans should not pay more for prescription drugs than patients in other developed countries. It directs the Secretary of Health and Human Services (HHS) to establish MFN price targets within 30 days and communicate these to pharmaceutical manufacturers.

• Direct-to-Consumer Sales: HHS is instructed to facilitate programs allowing pharmaceutical manufacturers to sell directly to American patients at MFN prices, potentially reducing reliance on intermediaries.

• Addressing International Pricing Disparities: The Secretary of Commerce and the U.S. Trade Representative are directed to take action against foreign practices that may contribute to higher drug prices in the U.S., ensuring that American patients do not disproportionately fund global pharmaceutical research and development.

Potential Impact:

While the executive order sets forth ambitious goals to reduce drug prices, its implementation may face challenges, including legal scrutiny and resistance from stakeholders concerned about its impact on innovation and global pricing dynamics. The effectiveness of the order will depend on the specifics of the forthcoming regulations and the responses from pharmaceutical companies and international partners.

Call to Action:

Healthcare providers, insurers, and pharmaceutical companies should closely monitor developments related to this executive order. For a comprehensive analysis of its implications and guidance on navigating the evolving regulatory landscape, contact Lanton Law today.

New Federal Directives to Enhance U.S. Drug Manufacturing: Compliance Insights for Healthcare

On May 5, 2025, President Donald Trump signed the Executive Order on Regulatory Relief to Promote Domestic Production of Critical Medicines, marking a significant move to reduce America's reliance on foreign pharmaceutical manufacturing. This initiative aims to streamline regulatory processes, making it more feasible for domestic facilities to produce essential medicines.

Key directives include:

• FDA Regulatory Streamlining: The Food and Drug Administration (FDA) is tasked with reviewing and eliminating redundant regulations within 180 days to expedite the approval of domestic pharmaceutical manufacturing facilities.

• Enhanced Oversight of Foreign Producers: The FDA will increase inspections of overseas facilities to ensure they meet U.S. standards, aiming to level the playing field for domestic manufacturers.

• Accelerated Facility Construction: The Environmental Protection Agency is directed to expedite the permitting process for building pharmaceutical manufacturing plants in the U.S., addressing the current 5 to 10-year timeline deemed unacceptable for national security.

This executive order underscores a strategic pivot towards bolstering national security through domestic production of critical medicines. Healthcare organizations involved in pharmaceutical manufacturing, supply chain management, or regulatory compliance must assess their operations in light of these changes.

At Lanton Law, we specialize in guiding healthcare businesses through complex regulatory landscapes. Our expertise ensures your organization remains compliant and competitive. To understand how this executive order impacts your operations and to develop a proactive compliance strategy, contact us today.

Healthcare Compliance Alert: Navigating the New Biological Research Safety Mandates

On May 5, 2025, President Donald Trump signed the Executive Order on Improving the Safety and Security of Biological Research, marking a pivotal shift in U.S. biosecurity policy. This directive halts federal funding for "dangerous gain-of-function" (GoF) research, particularly in countries like China and Iran, where oversight is deemed insufficient. The move responds to concerns that such research—enhancing pathogens' transmissibility or virulence—could lead to lab accidents with catastrophic consequences, as speculated in the origins of COVID-19.

The order mandates the Office of Science and Technology Policy (OSTP) to collaborate with federal agencies to:

• Cease funding for high-risk GoF research abroad.

• Suspend ongoing domestic projects involving dangerous pathogens.

• Develop a comprehensive oversight framework within 120 days.

• Implement stringent compliance clauses in federal research contracts.

Healthcare entities engaged in biomedical research must now navigate a complex regulatory landscape. Compliance isn't optional; it's imperative. Institutions must audit current projects, reassess collaborations, and ensure alignment with the forthcoming policies.

At Lanton Law, we specialize in guiding healthcare organizations through regulatory transformations. Our expertise ensures that your research initiatives remain compliant and ethically sound. To understand how this executive order impacts your operations and to develop a proactive compliance strategy, contact us today.